The growing threat of antimicrobial resistance (AMR) is driving rapid advancements in diagnostic technologies. Next-generation solutions such as whole-genome sequencing and multiplex point-of-care testing (POCT) are addressing critical challenges in pathogen identification, treatment selection, and infection control.
Industry Shifts & Analysis
-
The AMR diagnostics landscape is evolving with molecular platforms gaining traction due to their high accuracy and rapid turnaround times.
-
The sector is led by bioMérieux, Danaher, and Thermo Fisher Scientific, with the top three competitors commanding 84% revenue share.
-
Strategic mergers and acquisitions, such as bioMérieux’s acquisition of Specific Diagnostics and Roche’s acquisition of GenMark, are shaping the competitive landscape.
Strategic Imperatives
-
Technological Disruption: The integration of AI-driven whole-genome sequencing (WGS), next-generation sequencing (NGS), and microfluidics is revolutionizing AMR testing.
-
Market Expansion: The demand for multiplex POCT in decentralized settings (local clinics, pharmacies, and rural healthcare centers) is unlocking new growth avenues.
-
Collaborative Business Models: Public-private partnerships are essential to expanding diagnostic access and improving affordability in low-resource settings.
Explore the complete industry outlook and competitive intelligence in our latest analysis.
Download Sample
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
Upon completing the dialog session, you will receive a $1,000 honorarium* as a token of our appreciation, which can be used towards the purchase of our products and services on store.frost.com.
*$1,000 honorarium is subject to eligibility
